Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive

Vaccine

Volumn 28, Issue 8, 2010, Pages 1932-1941

  Hutnick, Natalie A ^a   Carnathan, Diane ^a   Demers, Korey ^a   Makedonas, George ^a   Ertl, Hildegund C J ^b   Betts, Michael R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

Adenovirus; Human; T cell

Indexed keywords

ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; CD27 ANTIGEN; CD45RO ANTIGEN; GAMMA INTERFERON; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMPANZEE; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; MOLECULAR RECOGNITION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SEROTYPE; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS IMMUNITY;

ADENOVIRUSES, HUMAN; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CROSS REACTIONS; CYTOKINES; FLOW CYTOMETRY; HUMANS; IMMUNITY, CELLULAR; PAN TROGLODYTES; T-LYMPHOCYTE SUBSETS;

EID: 76949105650     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.091     Document Type: Article

References (20)

1. Casimiro D.R., Bett A.J., Fu T.M., Davies M.E., Tang A., Wilson K.A., et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 78 (2004) 11434-11438
2. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77 (2003) 6305-6313
3. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 46 (2008) 1769-1781
4. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., and Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77 (2003) 799-803
5. McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M.O., Hensley S.E., Lin S.W., et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 81 (2007) 6594-6604
6. Xiang Z., Li Y., Cun A., Yang W., Ellenberg S., Switzer W.M., et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 12 (2006) 1596-1599
7. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174 (2005) 7179-7185
8. Calcedo R., Vandenberghe L.H., Roy S., Somanathan S., Wang L., and Wilson J.M. Host immune responses to chronic adenovirus infections in human and nonhuman primates. J Virol 83 (2009) 2623-2631
9. Leen A.M., Christin A., Khalil M., Weiss H., Gee A.P., Brenner M.K., et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 82 (2008) 546-554
10. Leen A.M., Myers G.D., Bollard C.M., Huls M.H., Sili U., Gee A.P., et al. T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci 1062 (2005) 104-115
11. Leen A.M., Sili U., Vanin E.F., Jewell A.M., Xie W., Vignali D., et al. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood 104 (2004) 2432-2440
12. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 372 (2008) 1894-1905
13. Tang J., Olive M., Champagne K., Flomenberg N., Eisenlohr L., Hsu S., et al. Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele. Gene Ther 11 (2004) 1408-1415
14. Veltrop-Duits L.A., Heemskerk B., Sombroek C.C., Van Vreeswijk T., Gubbels S., Toes R.E., et al. Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus. Eur J Immunol 36 (2006) 2410-2423
15. Tang J., Olive M., Pulmanausahakul R., Schnell M., Flomenberg N., Eisenlohr L., et al. Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology 350 (2006) 312-322
16. Crawford-Miksza L., and Schnurr D.P. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol 70 (1996) 1836-1844
17. De Jong J.C., Wermenbol A.G., Verweij-Uijterwaal M.W., Slaterus K.W., Wertheim-Van Dillen P., Van Doornum G.J., et al. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol 37 (1999) 3940-3945
18. Olive M., Eisenlohr L., Flomenberg N., Hsu S., and Flomenberg P. The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Hum Gene Ther 13 (2002) 1167-1178
19. Tatsis N., Fitzgerald J.C., Reyes-Sandoval A., Harris-Mccoy K.C., Hensley S.E., Zhou D., et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110 (2007) 1916-1923
20. Makedonas George, Hutnick Natalie, Haney Danielle, Amick Alexandra, Gardner Jay, Hersperger Adam R, et al. Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8+ T cells, submitted for publication.